Mentioned Timothy P.

ARIAD Pharmaceuticals initiates ponatinib Phase 2 trial in adult patients with metastatic GIST ARIAD Pharmaceuticals, Inc. The trial is made to provide initial medical data analyzing the efficacy and protection of ponatinib in sufferers with GIST following failure of prior tyrosine kinase inhibitor therapy. KIT is a clinically validated oncogenic target for GIST and may drive approximately 85 % of these cancers. In preclinical studies ponatinib was highly potent against activated KIT and most of its resistance mutants, mentioned Timothy P.[3] If all human generated PM2.M. Mannucci. European Heart Journal. Doi:10.1093/eurheartj/eht045.. ARYx Therapeutics reports net loss of $5.8M for fourth-quarter 2009 ARYx Therapeutics, Inc. today reported results of procedures and provided an revise on its products for the fourth quarter december 31 and 12 months ended, 2009. ‘2009 was a year of mixed outcomes for ARYx. We continuing to progress with the advancement of our three lead product candidates towards achievement of the prospective profiles we’d set for them. Nevertheless, the consequence of not completing a licensing contract for budiodarone, our novel antiarrhythmic agent, to a large pharmaceutical business left ARYx in a hard situation.